Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
Authors
Keywords
Apoptosis, DNA damage, Cell cycle and cell division, Acute myeloid leukemia, Cancer treatment, Flow cytometry, Reverse transcriptase-polymerase chain reaction, Cell staining
Journal
PLoS One
Volume 8, Issue 11, Pages e79106
Publisher
Public Library of Science (PLoS)
Online
2013-11-12
DOI
10.1371/journal.pone.0079106
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia
- (2013) I. Gojo et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- (2012) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcriptional and Nontranscriptional Functions of E2F1 in Response to DNA Damage
- (2011) A. K. Biswas et al. CANCER RESEARCH
- Therapeutic Advances in Acute Myeloid Leukemia
- (2011) Alan Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia
- (2011) Shuiying Hu et al. JNCI-Journal of the National Cancer Institute
- Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
- (2011) Xuelian Xu et al. PLoS One
- Anticancer therapy with checkpoint inhibitors: what, where and when?
- (2011) Michelle D. Garrett et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia
- (2010) C. Xie et al. CLINICAL CANCER RESEARCH
- Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
- (2010) R. Plummer CLINICAL CANCER RESEARCH
- Histone H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
- (2010) C. E. Redon et al. CLINICAL CANCER RESEARCH
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
- The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
- (2010) Paul A Marks EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
- (2010) A Quintás-Cardama et al. LEUKEMIA
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
- (2010) Julia M. Wagner et al. Clinical Epigenetics
- RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia
- (2009) H. Edwards et al. BLOOD
- Targeting the Molecular Defect in BRCA-Deficient Tumors for Cancer Therapy
- (2009) Ashok R. Venkitaraman CANCER CELL
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- Clinical Studies of Histone Deacetylase Inhibitors
- (2009) H. M. Prince et al. CLINICAL CANCER RESEARCH
- Targeting the DNA damage response for cancer therapy
- (2009) Simon N. Powell et al. DNA REPAIR
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
- (2008) Nagma Khan et al. BIOCHEMICAL JOURNAL
- Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
- (2008) G. Garcia-Manero et al. BLOOD
- Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
- (2008) L Nolan et al. BRITISH JOURNAL OF CANCER
- Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes
- (2008) V. M. Klimek et al. CLINICAL CANCER RESEARCH
- The consequences of Rad51 overexpression for normal and tumor cells
- (2008) Hannah L. Klein DNA REPAIR
- A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
- (2008) Peter Gimsing et al. EUROPEAN JOURNAL OF HAEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started